Personalis’ (PSNL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Personalis (NASDAQ:PSNL) in a research report sent to investors on Friday,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright also issued estimates for Personalis’ FY2029 earnings at $0.33 EPS.

Several other research firms have also commented on PSNL. Lake Street Capital upped their price target on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Needham & Company LLC decreased their target price on shares of Personalis from $7.25 to $7.00 and set a “buy” rating for the company in a research report on Friday.

Personalis Price Performance

PSNL stock opened at $4.14 on Friday. Personalis has a 1-year low of $1.13 and a 1-year high of $7.20. The firm has a fifty day moving average price of $5.40 and a two-hundred day moving average price of $5.04. The firm has a market cap of $292.48 million, a price-to-earnings ratio of -2.46 and a beta of 1.73.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.09. The business had revenue of $16.80 million during the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. As a group, analysts expect that Personalis will post -1.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Personalis

Institutional investors and hedge funds have recently bought and sold shares of the stock. Lightspeed Management Company L.L.C. bought a new position in shares of Personalis during the 4th quarter valued at about $47,169,000. ARK Investment Management LLC boosted its position in shares of Personalis by 11.4% during the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock valued at $38,120,000 after purchasing an additional 723,637 shares in the last quarter. abrdn plc bought a new position in shares of Personalis during the 4th quarter valued at about $1,722,000. Dimensional Fund Advisors LP boosted its position in shares of Personalis by 144.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock valued at $2,372,000 after purchasing an additional 242,141 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Personalis by 144.3% during the 4th quarter. Jane Street Group LLC now owns 401,314 shares of the company’s stock valued at $2,320,000 after purchasing an additional 237,033 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.